Kura Oncology, Inc. (KURA)
$10.40-1.89%Close
SELLBEAR · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $923M
- Beta
- 0.38
- P/E (TTM)
- -3.12
- Short % float
- 16.77%
- Days to cover
- 7.7
- SI change
- -2.7%
- 1W
- -2.07%
- 1M
- -8.69%
- vs SPY 1W
- -2.49%
- vs SPY 1M
- -10.75%
Industry peers
FMP comparable companies · ranked by market cap
- HCMBUYHUTCHMED (China) Limited$2.5BRECOVERYQ 5$14.10-2.98%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.85%
- SLSSELLSELLAS Life Sciences Group, Inc.$2.2BRECOVERYQ -9$11.65+2.40%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 16$16.99-2.59%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-1.50%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.94-1.71%
- RIGLBUYRigel Pharmaceuticals, Inc.$908MBULLQ 9$49.08-0.55%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-1.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KURA?
- LOPJLB’s latest quantitative signal on Kura Oncology, Inc. (KURA) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is KURA in?
- Kura Oncology, Inc. (KURA) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Kura Oncology, Inc. (KURA) do?
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted the…